Floatz logo

Inno-206

Metastatic Pancreatic Adenocarcinoma

OHSU Knight Cancer InstitutePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Metastatic Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Olaparib
Lantern Pharma Inc.
Phase 3BB
Epirubicin
Minia University
Phase 3BB
Irinotecan Sucrosofate
SWOG Cancer Research Network
Phase 3BB
Pembrolizumab
Mayo Clinic
Phase 2BB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →